MLECW
Moolec Science S.A.
NASDAQ · Healthcare · Biotechnology · LU
$0.01
−14.15%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -98.9%
- EBITDA
- —
- EPS
- +84.3%
Three-year CAGR
- Revenue
- +1819.9%
- EBITDA
- —
- EBIT
- -15.9%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025